CLINICAL_TRIALS
trial_result
· 2013-06-26
Clinical Trial Update: Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer [Phase 3]
Summary
A Phase 3 trial evaluating docetaxel plus prednisone for hormone-refractory metastatic prostate cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tampere University | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED